+1 617 937 2316 mrecht@cooley.com
For nearly 20 years, Marc Recht has represented life sciences and other healthcare companies and investors in public and private transactions, including securities offerings and M&A matters. He also has extensive experience advising public companies boards of directors and management teams regarding Securities and Exchange Commission periodic disclosure, Sarbanes-Oxley compliance, corporate governance and Nasdaq and New York Stock Exchange rules.
Download full bio
Prevail Therapeutics Closes $50 Million Series B
Morphic Therapeutics - $104 Million IPO
Prevail Therapeutics $125 Million IPO
Milestone Pharmaceuticals – $95 Million IPO
Genfit - $155 Million IPO
View all
Public Companies
Capital Markets
Life Sciences
Mergers & Acquisitions
Emerging Companies
Medtech
Digital Health
Venture Capital
Road cycling
Skiing
Excellent in all categories. Marc Recht is 'very technically skilled in corporate matters and plays a strong quarterback role.'
Boston College Law SchoolJD, magna cum laude, 1999
Brandeis University BA, with honors, 1995
Massachusetts
New Batch of More Mature Biotech Startups Makes Public Market Debut May 9, 2019
Chambers USA 2019 Recognizes Cooley Lawyers + Practices April 30, 2019
Scholar Rock – $86 Million IPO June 18, 2018
Chambers USA: Corporate/M&A: Capital Markets - Massachusetts (2014-2019)
The Legal 500 US: Life Sciences and Healthcare (2013, 2016)
Who's Who Legal: Life Sciences (2017, 2018)
Super Lawyers: Rising Star (2007, 2010-2013)
Boston Business Journal: Biotech IPO (2015)
+1 617 937 2316 office +1 617 937 2400 fax mrecht@cooley.com
500 Boylston Street14th FloorBoston, MA 02116-3736